- Market : Korea
- Symbol : 078160
- ISIN : KR7078160009
- Industry : Pharmaceuticals
MEDIPOST is a leading stem cell biotechology company focused on developing products to meet unmet
medical needs such as those related to regenerative or functional recovery of knee articular cartilage, the
nervous system, the pulmonary system and hematopoietic transplantation engraftment areas.
MEDIPOST provides services and develops products related to a readily available and non-controversial
source - human umbilical cord blood and human umbilical cord blood derived mesenchymal stem cells
The stem cells, coming from unrelated healthy donors, have demostrated the
ability to regenerate and/or to recover functionality of different types of damaged tissues.
Such adult stem cell therapies having an "off-the-self"concept revolutionize medical treatments and bring about a new era of mass-manufactured allogeneic stem cell drug products.
|Yearly Income Statement (KRW mn)
|Cord blood bank
|Stem cell therapy
|Summarized Financial Statements (KRW mn)
|R&D Investment (KRW mn)
|R&D /Sales (%)
- Contact Investor Relations
- Tel.: +822-3465-6615
- Fax: +822-3465-6688
- E-mail: email@example.com
- ADD 21, Daewangpangyo-ro 644 (Sampyeong- dong), Bundang-gu, Seongnam-si, Gyeonggi-do, Korea